TEK2day FINANCE Open Terminal →

Journey Medical Corporation (DERM)

NCM · Healthcare · Drug Manufacturers - Specialty & Generic

$6.34 +1.12%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History -9.0% over period
$10$8$7$5$4 2025-062025-092025-122026-032026-06

Key Metrics

Market Cap
$136.5M
Shares Outstanding
21.5M
P/S (TTM)
2.1x
Exchange
NCM
Currency
USD

About Journey Medical Corporation

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Quarterly Financials

Metric2025-06-302025-09-302025-12-312026-03-31
Revenue15.0M17.6M16.1M16.0M
Gross Profit10.1M11.9M10.6M9.7M
Operating Income-2.9M-1.5M-443K-1.5M
Net Income-3.8M-2.3M-1.2M-2.2M
Diluted EPS$-0.16$-0.09$nan$-0.08

Annual Financials

Metric2022-12-312023-12-312024-12-312025-12-31
Revenue73.7M79.2M56.1M61.9M
Gross Profit42.9M56.3M35.3M40.9M
Operating Income-27.5M1.1M-18.2M-8.2M
Net Income-29.6M-3.9M-14.7M-11.4M
Diluted EPS$-1.69$-0.21$-0.72$nan
Want live quotes, estimates, SEC filings, and CEO analytics for DERM?
The free TEK2day terminal runs in your browser — type /DERM to get started.
Open DERM in the Terminal →